Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients BOSTON–(BUSINESS WIRE)–Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. […]
Tag: Elucid Bio
Elucid Bio’s vascuCAP enters IBM Imaging AI Marketplace
BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution. The IBM Imaging AI Marketplace provides streamlined access to meaningful AI technologies designed to support leaders […]
Study Demonstrates that AI Technology is Better Predictor of Stroke than Traditional Methods, Elucid Bio Announces
Dr. Brajesh Lal of the University of Maryland Presents Study Data at the Society for Vascular Surgery Conference July 01, 2020 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Elucid Bio, maker of the FDA-cleared and CE-marked vascuCAP® software, announced today that its novel artificial intelligence (AI) technology demonstrated an over 70 […]



